Population Reference Ranges Versus Individual Targets

Two Different Kinds of Guidance

A concentration can be outside a population therapeutic reference range and still be the exposure at which a particular patient has obtained sustained benefit without unacceptable adverse effects. Conversely, a concentration inside the range does not ensure that the patient is benefiting or tolerating treatment. These statements are not contradictory: a population range summarizes evidence across patients, while an individual target is informed by one patient’s history.

In therapeutic drug monitoring, a population range can help identify concentrations that commonly support an acceptable balance of benefit and harm for a specified treatment context. It can guide initial interpretation when a patient’s own exposure–response history is limited. Once a patient has an established effective and tolerated exposure, that history provides additional, patient-specific evidence. It should be considered alongside—not automatically replaced by—the population range.

The word “reference range” can also describe a statistical interval covering much of the observed values in a reference population. That is not necessarily the meaning of a therapeutic reference range. A therapeutic range is intended to inform treatment; it is not simply a summary of concentrations measured in healthy people. Its scope depends on the drug, indication, patient group, evidence, and the exposure measure being interpreted.

What Makes an Individual Target Informative?

An individual target is most informative when the exposure was measured under conditions that can be compared with the current measurement and when the clinical history is interpretable. The relevant history includes whether the patient had a meaningful clinical benefit, whether adverse effects were acceptable, and whether the regimen and clinical context were sufficiently stable to connect that outcome with the measured exposure.

A past concentration alone does not establish an individual target. For example, an exposure recorded during a period of poor response is not evidence that the exposure was effective. Nor does one uneventful measurement prove long-term safety. The inference is stronger when response and tolerability were observed over an appropriate period and relevant clinical factors were documented. Exposure may be only one influence among disease severity, co-medications, adherence, and other patient characteristics.

Comparison also requires like-for-like measurements. The exposure metric, units, assay, and sampling context should be sufficiently comparable. A numerical difference between unlike measurements may reflect how or when they were obtained rather than a real change in the patient’s exposure. The specific metric and sampling procedures are separate considerations; here the essential point is that a target and a measured value must refer to comparable quantities.

A useful formal distinction is to represent the population range as \(R=[L,U]\), where \(L\) and \(U\) are its lower and upper bounds. For a patient \(i\), let \(I_i\) denote the set of exposures supported by that patient’s effective and tolerated treatment history. The sets need not coincide:

An individual target need not be an interval: sometimes the evidence supports a useful benchmark concentration but not precise personal boundaries. Writing \(I_i\) as a band is appropriate only when observations support a band, rather than when the limits are chosen merely for convenience.

Why Population and Individual Targets Can Differ

A population range summarizes evidence across people who may differ in sensitivity, disease features, metabolism, concurrent treatments, and susceptibility to adverse effects. A concentration associated with acceptable outcomes for many patients may therefore not be the best-supported exposure for a specific patient. Some patients may respond at concentrations below the range; others may require concentrations above it, or may experience adverse effects well within it.

This can be expressed using conditional outcomes. A population range concerns the relationship between exposure and outcomes across a defined group. An individual target concerns the evidence about outcomes for patient \(i\), given that patient’s characteristics and history. In general, the average pattern across a group does not determine an individual’s pattern:

This distinction justifies taking a documented patient history seriously, but it does not prove that the measured exposure caused the observed outcome. A patient’s response may have changed for other reasons, and the historical concentration may be imprecise or unrepresentative. The individual target is evidence to weigh, not an immutable biological constant.

Interpreting Disagreement in Practice

A disagreement between the two targets is a reason to examine the evidence, not to choose one number mechanically. The strength of the patient-specific evidence depends on how clearly exposure, response, and tolerability were linked in time and how well the historical and current measurements can be compared. When a patient’s own history is sparse or uncertain, the population range may carry more weight. When the patient has a well-documented stable response at a comparable exposure, that history adds evidence not captured by the population average.

A practical review can proceed in a consistent order:

The main alternatives are not simply “follow the population range” and “ignore it.” A population-first approach is helpful when patient-specific evidence is absent, weak, or no longer applicable. An individual-history-first approach is more informative when a patient has a reliable record of effective and tolerated treatment, but it can mislead if that history is mistaken for proof of causation or treated as permanently valid. A combined approach uses the range as a population-level reference and the patient’s history as additional evidence, then investigates meaningful discrepancies.

Diagnostics, Failure Modes, and Limitations

• Check for a mismatched comparison. Different metrics, units, assays, or sampling contexts can create an apparent difference that is not clinically interpretable.
• Check whether the historical benchmark was truly effective and tolerated. A concentration observed during poor response, or without adequate information about adverse effects, cannot establish an effective-and-tolerated target.
• Check whether the patient’s context has changed. A previously useful benchmark may not apply after a meaningful change in disease status or treatment circumstances.
• Do not treat range membership as a clinical outcome. An in-range value does not itself demonstrate benefit or safety, and an out-of-range value does not itself demonstrate treatment failure or toxicity.
• Do not claim causation from a concentration difference alone. A change in exposure and a change in symptoms may occur together without one causing the other.

An important limitation is that individual targets are often less precisely estimated than population ranges. A patient may have only a few observations, and clinical outcomes may be influenced by factors that were not recorded. Population ranges also depend on the evidence and patient group used to define them; they may not represent every subgroup equally well. Therefore, disagreement should prompt transparent assessment of evidence quality and current clinical circumstances, not false precision about a personal “correct” concentration.

Common Mistake

Wrong reasoning: “The concentration is within the therapeutic range, so the dose must be right,” or, conversely, “The concentration is below the range, so the dose must be increased.”

Correction: A population range is a guide for a defined population, not a guarantee of an individual outcome or a mandatory boundary for every patient. Interpret the measurement with the patient’s documented response and tolerability, ensure the comparison is valid, and assess other relevant clinical information before drawing a conclusion. A concentration result informs clinical judgment; it does not replace it.